Taken together, our findings demonstrate that GSAP cleavage via caspase-3 is regulated and depend upon the availability of 5LO further establishing this protein as an attractive and viable therapeutic target for Alzheimer’s disease. The gene discussed is CASP3; the disease is early-onset autosomal dominant Alzheimer disease.